Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabKimio Yonesaka, Pasi A. Jänne, Kreshnik Zejnullahu et al.|Science Translational Medicine|2011Cited by 670
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatmentKoji Haratani, Kazuhiko Nakagawa, Kaoru Tanaka et al.|Annals of Oncology|2017Cited by 294
B7-H3 Negatively Modulates CTL-Mediated Cancer ImmunityKimio Yonesaka, Kazuhiko Nakagawa, Koji Haratani et al.|Clinical Cancer Research|2018Cited by 169
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary SiteHidetoshi Hayashi, Kazuhiko Nakagawa, Takayasu Kurata et al.|Journal of Clinical Oncology|2019Cited by 168
Activation of HER Family Signaling as a Mechanism of Acquired Resistance to ALK Inhibitors in EML4-ALK–Positive Non–Small Cell Lung CancerJunko Tanizaki, Kazuhiko Nakagawa, Isamu Okamoto et al.|Clinical Cancer Research|2012Cited by 156